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ABSTRACT 
Etoposide derives from podophyllotoxin, a toxin found in the American Mayapple. It was first synthesized in 
1966 and approved for cancer therapy in 1983 by the U.S. Food and Drug Administration (Hande, 1998). Start-
ing from 1980s several studies demonstrated that etoposide targets DNA topoisomerase II activities thus leading 
to the production of DNA breaks and eliciting a response that affects several aspects of cell metabolisms. In this 
review we will focus on molecular mechanisms that account for the biological effect of etoposide.  
 
 
ETOPOSIDE IS A TOPOISOMERASE II 
POISON 
Topoisomerase II-mediated DNA breaks 
DNA topoisomerases are essential en-
zymes that regulate the topological state of 
the genetic material by introducing transient 
breaks in the DNA molecule. They are in-
volved in fundamental biological processes 
such as DNA replication, transcription, DNA 
repair and chromatin remodeling. The un-
winding and rewinding of the double helix, 
the protein movement along DNA and the 
coiling of DNA in higher-order structures 
lead to topological entanglements that are 
resolved by topoisomerases by enabling top-
ological transformation through two trans-
esterification reactions. A tyrosine in the ac-
tive site of the enzyme initiates the first 
transesterification and forms a covalent ad-
duct with the phosphate in the backbone of 
the DNA molecule, thus generating a transi-
ent interruption of the double helix through 
which topological transformations can occur. 
The second transesterification reseals the 
DNA break (re-ligation) and regenerates the 
free tyrosine. Based on their structure and 
mechanism of action, topoisomerases are 
grouped into type I (TopoI) and type II 
(TopoII) enzymes. TopoI enzymes carry out 
strand passage through a single-stranded 
break, while TopoII activities involve the 
production of a double-strand break (Chen et 
al., 2013). TopoII can perform three kinds of 
reactions (Figure 1): while DNA relaxation 
is in common to TopoI, catenation/de-
catenation and knotting/unknotting are 
TopoII specific.  
 
Figure 1: Reactions catalyzed by type II topo-
isomerases. All these transformations are per-
formed by passing one double-stranded DNA 
segment through another. 
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The covalent topoisomerase-cleaved 
DNA complex, referred to as cleavable or 
cleavage complex, is a short-live intermedi-
ate in this reaction. However, it can be stabi-
lized by several compounds leading to the 
production of high levels of protein-
associated breaks in the genome that are ex-
tremely toxic for the cell.  
Etoposide poisons the TopoII cleavage 
complexes (TopoIIcc) and inhibits the sec-
ond step of the reaction (i.e. DNA re-
ligation). The recent high-resolution of the 
ternary complex between TopoII, DNA and 
etoposide has revealed the elements that are 
crucial to the stabilization of the cleavable 
complex. Interactions with specific amino 
acids of the enzyme are critical for etoposide 
to enter the TopoII-DNA complex. The ac-
tive role played by TopoII in promoting and 
stabilizing the ternary complex is consistent 
with the notion that the drug by itself dis-
plays low-affinity toward free DNA and is a 
poor DNA intercalator (Wu et al., 2011; 
Wilstermann et al., 2007). However a recent 
analysis indicates that etoposide has also a 
high-affinity for chromatin and histones, in 
particular H1, suggesting that beside TopoII, 
chromatin can be a target of the drug 
(Chamani et al., 2014). 
 
Clinical implications   
Mammals have two TopoII isoenzymes, 
TopoII and  that are differently regulated 
during cell growth (Nitiss, 2009). TopoII is 
a proliferation marker and is greatly elevated 
in tumor cells, whereas the  isoenzyme is 
present in proliferating as well as post-
mitotic cells. In agreement with this differen-
tial expression TopoII functions in cell cy-
cle events such as DNA replication and 
chromosome segregation, while TopoII has 
been implicated in transcription and is asso-
ciated with developmental and differentia-
tion programs (Yang et al., 2000; Lyu et al., 
2006; Tiwari et al., 2012). Although both 
TopoII isoenzymes are targets of etoposide, 
the relative contributions of TopoIIα and 
TopoII to the chemotherapeutic effects has 
yet to be resolved. Because TopoIIα is over-
expressed in tumor cells, it is an ideal target 
for anticancer drugs. However, it is still un-
clear whether the two isoenzymes play dif-
ferent roles in tumor-cell killing in response 
to etoposide or more in general to TopoII-
based chemotherapy.  
The issue of isoform specificity has po-
tential clinical implications. For instance, 
since TopoII is not expressed appreciably 
in quiescent cells, etoposide targeting of 
TopoII in differentiated tissues, such as 
cardiac cells, could account for much of the 
off-target toxicity of the drug (Azarova et al., 
2007). TopoII activity can be also involved 
in the drug-induced secondary malignancies, 
such as acute myelocytic leukemia (t-AML) 
and treatment-related myelodysplastic syn-
dromes (t-MDS) often progressing to t-AML 
(Pedersen-Bjergaard et al., 2002a, b), that 
have been noted in patients receiving 
TopoII-based chemotherapy.  
Etoposide-induced t-AML is frequently 
associated with balanced translocations be-
tween the mixed lineage leukemia (MLL) 
gene on chromosome 11q23 and several 
partner genes. This translocation appears to 
be linked to the trapping of a TopoIIcc in the 
MLL gene (Lovett et al., 2001a, b). In fact 
the break point cluster region in the MLL 
gene is AT-rich and contains Alu sequences, 
corresponding to putative recognition sites of 
TopoII-mediated DNA cleavage, and chro-
mosome scaffold/matrix attachment regions 
(SAR/MAR).  
Azarova and colleagues (Azarova et al., 
2007) used skin-specific TopoII-knockout 
mice to test whether the two isozymes have 
different roles in the development of second-
ary malignancies and in tumor-cell killing. 
Their results suggest that, at least in this ex-
perimental system, TopoII is the isoform 
responsible for etoposide-induced carcino-
genesis. Furthermore, in cell-culture models, 
etoposide-induced DNA sequence rear-
rangements and DSBs are also found to be 
primarily TopoII-dependent. By contrast, 
etoposide cytotoxicity in tumor cells ex-
pressing both isoenzymes appears to be 
mainly TopoII-dependent. Therefore, the 
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two isoenzymes play distinct roles in TopoII-
based chemotherapy, which points to the 
need of developing isoenzyme-specific drugs 
for cancer chemotherapy in order to reduce 
the risk of treatment-related secondary ma-
lignancies (Azarova et al., 2007). This task 
can be helped by the recent resolution of the 
crystal structure of a large fragment of hu-
man TopoII in a ternary complex with 
DNA and etoposide (Wu et al., 2011).  
Another important therapeutic issue is 
the development of etoposide resistance. One 
player in this phenomenon is the double mi-
nute 2 (MDM2) gene encoding an ubiquitin 
ligase involved in proteasome-mediated pro-
tein degradation. Interestingly, a single nu-
cleotide polymorphism (SNP) SNP309 (T/G) 
in the gene promoter produces MDM2 up-
regulation, and results in increased suscepti-
bility to cancer and decreased response to 
radiation therapy and DNA-damaging drugs 
including TopoII poisons. Indeed cancer cell 
lines homozygous for SNP309 are selective-
ly resistant (10-fold) to etoposide, mitoxan-
trone, amsacrine, and ellipticine. This effect 
arises from the ability of MDM2 protein to 
bind and target TopoII for degradation. 
Knockdown of MDM2 by RNAi stabilizes 
TopoII and decreases the resistance to 
TopoII-targeting drugs. Given the frequency 
of SNP309 in the general population (40 % 
of T/G heterozygosity and 12 % of G/G ho-
mozygosity), this polymorphism may repre-
sent a relatively common determinant of 
drug sensitivity with important implications 
for personalized cancer chemotherapy 
(Nayak et al., 2007). 
 
Processing and repair of the protein-DNA 
covalent adducts  
The prolonged presence of TopoII-
cleavage complexes and their associated sin-
gle and double strand DNA breaks interfere 
with a number of DNA transactions, such as 
DNA replication and transcription, and must 
be efficiently removed by the cell. The first 
step in this process is the displacement of the 
protein cap from 5’-end of the break in order 
to make it accessible to DNA repair machin-
eries.  
A few indirect mechanisms have been 
implicated in resolving the covalent link be-
tween TopoII and DNA. For instance, in the 
fission yeast Schizosaccharomyces pombe 
the nuclease activity of the Mre11/Rad50/ 
Nbs1 (MRN) complex, which is essential for 
repairing DSBs, removes TopoII from the 
DNA (Hartsuiker et al., 2009). This process 
requires also the CtIP function, a BRCA1 
interacting protein (Wong et al., 1998; Yu et 
al., 1998), which is recruited to sites of DNA 
damage (Sartori et al., 2007). However, de-
scribing a new Saccharomyces cerevisiae 
mutant allele, Hamilton and Maizels ob-
served that Mre11 have a role in response to 
topoisomerase poisons that can be also inde-
pendent of its function in DSBs repair (Ham-
ilton and Maizels, 2010). These observations 
reveal a role of the MRN complex and CtIP 
in the cell resistance to a clinically important 
group of anticancer drugs.  
Another mechanism has been discovered 
by Zhang and colleagues (Zhang et al., 2006) 
and involves the proteasome-mediated de-
gradation pathways in the processing of 
TopoII-DNA adducts. Using a number of 
experimental systems, including TopoII 
knock-out mouse embryonic fibroblasts, 
TopoII small interfering RNA knock-down 
PC12 cells, as well as post-mitotic neurons 
in which TopoII is absent, the authors have 
proven that etoposide-induced DNA damage 
signals are attenuated upon proteasome inhi-
bition with MG132. Moreover, by the analy-
sis of the response to etoposide treatment in 
four different tumor cell lines, Fan and 
coworkers have demonstrated that the pro-
teasome activity contributes to the pro-
cessing of TopoIIcc into protein-free DNA 
breakage for subsequent sensing and repair 
of the damage in a transcription-dependent 
manner (Fan et al., 2008b).  
More recently, a human 5’-tyrosine 
phosphodiesterase has been identified for the 
excision of TopoII-DNA adducts (Cortes 
Ledesma et al., 2009). TTRAP (TRAF and 
TNF receptor-associated protein) is a mem-
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ber of Mg2+/Mn2+-dependent family of phos-
phodiesterases that efficiently restore ligata-
ble 5’-phosphate termini on DNA double-
strand breaks. By analogy with the enzyme 
that removes TopoI-DNA adducts (tyrosine 
phosphodiesterase TDP1 (Nitiss et al., 
2006)), it has been renamed tyrosine phos-
phodiesterase 2 (TDP2) and represents the 
major 5’-TDP activity in vertebrate cells 
(Zeng et al., 2011; Gao et al., 2014). Nota-
bly, cellular depletion of TDP2 results in in-
creased sensitivity to etoposide-induced 
DSBs (Cortes Ledesma et al., 2009) and 
raises the possibility that TTRAP/TDP2 
plays a role in cancer development and re-
sponse to therapeutic treatments.  
Processing of TopoIIcc leads to cytotoxic 
DSBs. A direct correlation has been demon-
strated between the inability to repair DSBs 
and cell sensitivity to topoisomerase poisons 
(Hansen et al., 2003). Proliferating cells use 
different pathways to repair DSBs depending 
on cell cycle phases (Kakarougkas and Je-
ggo, 2014). In G1 DSBs are repaired by the 
low-fidelity non-homologous end-joining 
(NHEJ) pathway while homologous recom-
bination (HR) plays a role in S and G2. In-
terestingly, knock out of DNA ligase IV 
(LIG4-/-) and of the Ku70 subunit of Ku het-
erodimer (KU70-/-) in chicken DT40 cells, 
which completely impairs NHEJ, makes the 
cells extremely sensitive to etoposide. In 
contrast, DNA repair and recombination pro-
tein RAD54-/- knock out cells (defective in 
HR) are much less hypersensitive. Collec-
tively these results provide evidence that 
NHEJ is the predominant pathway for the 
repair of etoposide-induced TopoII-mediated 
DNA damage (Adachi et al., 2003). In 
agreement with this conclusion, Malik and 
coworkers have found that the fission yeast 
orthologs of Ku70 (hdf1) and Ku80 (hdf2), 
and other genes required for NHEJ, are im-
portant for the survival of Saccharomyces 
cerevisiae following exposure to etoposide 
(Malik et al., 2006). Moreover, Chen and co-
workers (Chen et al., 2007) have reported 
that the impairment of Ku70 function dimin-
ishes cellular capability to repair DSBs in-
duced by etoposide and doxorubicin, thus 
enhancing cell-killing activity. Notably, 
Ku70 mutations that mimic acetylation of 
specific lysine residues suppress the ability 
of Ku70 to bind DNA and render prostate 
cancer cell more susceptible to the effect of 
etoposide suggesting a role of Ku70 acetyla-
tion in the effect of histone deacetylase 
(HDAC) inhibitors (Chen et al., 2007). Fi-
nally, the analysis on several human tumor 
cells shows that NHEJ-mediated repair of 
etoposide-induced DNA lesions requires ac-
tive transcription or replication of damaged 
DNA (Fan et al., 2008a), reinforcing the hy-
pothesis that the interference with transcrip-
tion and replication machineries has a major 
role in the etoposide cytotoxicity. 
 
DNA damage response 
DNA damage induces an evolutionary 
conserved network of sensors, mediators and 
effectors, called DNA damage response 
(DDR), that sense the damage and spread the 
signal throughout the cell by a signal ampli-
fication cascade. As a consequence cell cycle 
progression is slowed-down or arrested to 
prevent the duplication and transmission of 
damaged DNA to daughter cells and to coor-
dinate DNA repair pathways (Bartek and 
Lukas, 2007).  
Single-stranded DNA and DSBs are 
sensed by specialized complexes that recruit 
to the lesions and activate two large protein 
kinases, ataxia telangiectasia and Rad3-
related (ATR) and ataxia-telangiectasia mu-
tated (ATM), resulting in the local phos-
phorylation of the histone variant H2AX 
(Maréchal and Zou, 2013). Phosphorylated 
H2AX (called γH2AX) in turn recruits addi-
tional ATM complexes in a positive feed-
back loop, thereby increasing local ATM ac-
tivity and causing the spread of γH2AX 
along the chromatin with the formation of 
the so-called γH2AX foci.  
Long stretches of single-stranded DNA 
derived by replication stress, are bound by 
the single-stranded DNA-binding protein 
replication protein A (RPA) and represent 
the signal for ATR recruitment. Therefore, 
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while DSBs primarily activate ATM, pro-
cessing of DSBs by specific endonucleases 
in S and G2 phases can produce extended 
single-stranded DNA regions, resulting in 
ATR activation indicating that both ATM 
and ATR kinases may be engaged at the 
same lesion. The local increase in the activi-
ty of these kinases causes the activation of 
two additional checkpoint kinases, Chk2 and 
Chk1 respectively, that diffuse throughout 
the nucleus and give raise to signaling path-
ways that converge on key decision-making 
factors, such as p53 and the cell-division cy-
cle 25 (CDC25) phosphatases. DDR activa-
tion triggers a deep reorganization of nuclear 
functional compartments with the formation 
of discrete nuclear foci to which damaged 
DNA, DNA repair enzymes and auxiliary 
factors are recruited (Giglia-Mari et al., 
2011; Polo and Jackson, 2011; Maréchal and 
Zou, 2013).  
As expected from its ability to induce 
DSBs, etoposide triggers the activation of 
ATM and of its downstream kinase Chk2. 
Mutations of the ATM kinase, as in the case 
of ataxia telangiectasia (AT) patients, result 
in hypersensitivity to etoposide (Caporossi et 
al., 1993). In particular, loss of the G2/M 
checkpoint in AT cells results in the execu-
tion of mitosis even in the presence of unre-
paired etoposide-induced DNA breaks lead-
ing to chromosomal abnormalities (Nakada 
et al., 2006). The activation of ATM kinase 
triggered by etoposide eventually leads to the 
formation of subnuclear repair foci contain-
ing the MRN (Mre11/Rad50/NBS1) complex 
and indistinguishable from ionizing radia-
tion-induced foci (IRIF) (Maser et al., 1997). 
The focal accumulation of DNA repair fac-
tors, including MRN complex and γH2AX is 
a key cytological signature of the DNA dam-
age response. Although these foci have been 
extensively studied by light microscopy, lit-
tle is known about their ultrastructure. Using 
correlative light microscopy and electron 
spectroscopic imaging (LM/eSI) Dellaire and 
colleagues (Dellaire et al., 2009) have char-
acterized the ultrastructure of chromatin and 
DNA repair foci within the nuclei of normal 
human fibroblasts in response to etoposide. 
They have observed a global decrease in 
chromatin density, which is accompanied by 
the formation of invaginations of the nuclear 
envelope. By time course experiments with 
dual immunogold labeling of Mre11 and 
γH2AX they have shown that DNA repair 
foci are highly dynamic and that late foci 
exhibit a highly organized chromatin ar-
rangement distinct from earlier repair foci 
(Dellaire et al., 2009). Interestingly, we have 
found that etoposide also exerts an effect on 
the functional organization of replication foci 
and factories, which are the subnuclear com-
partments where DNA replication takes 
place. During S phase, this drug progressive-
ly affects the distribution of replication pro-
teins, triggering the dispersal of replication 
factories and inducing the formation of large 
nuclear foci containing single-strand DNA 
binding protein RPA (Rossi et al., 2006). 
The subnuclear reorganization of replicative 
structures is also accompanied by a change 
in the phosphorylation pattern of replication 
proteins, i.e. RPA and DNA ligase I (Mon-
tecucco et al., 2001; Rossi et al., 2002) and 
requires the activity of ATR kinase and the 
cooperation of Nbs1, a partner of Mre11 nu-
clease in the MRN complex. Notably cells 
exposed to the topoisomerase II inhibitor, 
ICRF-193, or to the radiomimetic drug ble-
omycin, do not undergo the dispersal of re-
plication factories even if checkpoint kinases 
are activated. Therefore, dispersal of replica-
tion foci elicited by etoposide does not de-
pend on topoisomerase II inhibition or on the 
formation of DSBs per se, but requires the 
processing of the poisoned cleavage com-
plexes.  
The effect on the subcellular distribution 
of proteins is not limited to the replication 
compartments. Indeed, using spatial prote-
omics, a mass spectrometry-based approach 
for measuring the subcellular distribution of 
the proteome, Lamond group has recently 
observed that etoposide treatment of 
HCT116 cells results in the dissociation of 
the proteasome from inhibitory proteins in 
the cytoplasm and its re-location in the nu-
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cleus with the ensuing association with pro-
teasome activators (Boisvert et al., 2010). 
 
CHROMATIN PERTURBATION AND 
TRANSCRIPTION  
Nuclear functions such as DNA replica-
tion and transcription are carried out within a 
highly organized three-dimensional envi-
ronment, which starts with the packaging of 
DNA and associated proteins into chromatin. 
Post-translational histone modifications 
(PTMs) by affecting the higher-order chro-
matin structure directly influence the gene 
function, either activating or inhibiting tran-
scription depending on the type of PTM, the 
residue which is modified and the distribu-
tion of modified histones along the gene 
(Schneider and Grosschedl, 2007). Among 
histone PTMs, acetylation appears to influ-
ence the response to etoposide treatments.  
The acetylation state of lysine residues, 
including those at the N-terminal ‘tail’ of the 
histones, is controlled by histone deacetylas-
es (HDACs) and histone acetyltransferases 
(HATs) that also modulate the acetyla-
tion/deacetylation status of non-histone pro-
teins, including transcription factors and co-
regulators (Hermanson et al., 2002; Glozak 
et al., 2005; Liu et al., 2009). Several exper-
imental evidences link HDACs and HATs to 
TopoII and to the response to etoposide 
treatment.  For instance, HDAC1/2 have 
been found in a functional complex with 
TopoII in vivo (Tsai et al., 2000), and 
TopoII is an integral component of the 
NuRD complex which also contains 
HDAC1/2 and an ATP-dependent chromatin 
remodeling activity (Tong et al., 1998). 
These interactions may account for the ob-
servation that the etoposide concentration 
required to inhibit cell growth by 50 % (IC50) 
is significantly decreased when cells are sub-
jected to pre-treatment with the HDACs in-
hibitor (HDACi) trichostatin A (TSA). 
Along this line it is worth noticing that 
HDACi also induce sensitization to etopo-
side of multidrug-resistant cancer cells (Hajji 
et al., 2008; Hajji et al., 2010). This effect is 
associated with an increased acetylation of 
particular lysines on histone H3 and H4, in-
cluding lysine 16 on histone H4 (H4K16). 
Notably, overexpression of histone acetylase 
hMOF, known to target H4K16, can mimic 
HDACi treatment, while overexpression of 
SIRT1 deacetylase counteracted the effect, 
pointing to hMOF and SIRT1 activities as 
critical parameters in HDACi-mediated sen-
sitization to etoposide. Moreover, TSA 
treatment displaces TopoII from its binding 
to heterochromatin (Cowell et al., 2011). 
Although the underlying molecular mecha-
nism is till to be defined, the displacement 
can convert TopoII to an effective relevant 
target for topoisomerase poisons.  
The melanoma antigen 1 (MageA1) is 
one of the first identified tumor-specific an-
tigens (van der Bruggen et al., 1991). Emerg-
ing data suggest the potential involvement of 
MAGE family proteins in modulating cell 
survival with two MAGE-II members, Nec-
din and hNRAGE, oppositely modulating 
p53 functions (Taniura et al., 1999; Wen et 
al., 2004). Claudio Schneider group (Monte 
et al., 2006) has reported that MageA2 inter-
acts and represses p53 activity by recruiting 
transcription repressors HDACs to p53 tran-
scription sites and inducing histone hypo-
acetylation in melanoma cells. Interestingly, 
melanoma cells expressing MAGE-A genes 
are refractory to etoposide-induced apopto-
sis. The correlation between MAGE-A ex-
pression and resistance to apoptosis has been 
validated in melanoma cell lines, where 
combined TSA and etoposide treatment re-
stores the p53 response and reverts the 
chemoresistance of cells expressing high 
levels of MAGE-A. 
Chromatin organization and chromosome 
territories may be actually targets of etopo-
side treatment. In this regard it is worth no-
ticing that repositioning of TopoIIcc could 
account for the relocation of the ETO/MTG8/ 
RUNX1T1 gene (located on chromosome 8) 
in physical proximity to the AML1 gene (on 
chromosome 21) observed in cycling cells 
upon etoposide treatment. Rubtsov and col-
leagues (Rubtsov et al., 2008) have suggest-
ed a link between this redistribution and the 
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t(8;21)(q22;q22) translocation that is fre-
quently observed in acute myeloid leukemia 
(AML) (Zhang et al., 2002).  
Another connection between etoposide, 
chromatin organization and gene expression 
has been recently reported by Huang and 
coworkers (Huang et al., 2012). These au-
thors showed the ability of etoposide and 
other topoisomerase inhibitors to un-silence 
gene expression by repressing transcription 
of cis acting non-coding RNA. This fascinat-
ing finding concerns the dormant allele of 
UBE3A gene whose mutation causes the neu-
rodevelopmental disorder known as Angel-
man syndrome. In neuron, the paternal allele 
of the ubiquitin protein ligase E3A (UBE3A) 
is intact but epigenetically silenced by an 
imprinted antisense RNA. Etoposide treat-
ment un-silences the paternal allele reducing 
the transcription level of the cis acting anti-
sense RNA. This observation, besides sug-
gesting a potential therapy for patient bear-
ing mutations in the UBE3A maternal allele, 
sheds a new light on additional molecular 
mechanisms and therapeutic potential of 
TopoII poisons. 
A further mechanism through which 
etoposide can down-regulate transcription of 
specific genes, has been unveiled by Takami 
and colleagues (Takami et al., 2011) that, by 
screening a library of phage-displayed pep-
tides, identified transcription factor E2F-4 as 
an etoposide binding protein. Binding of 
E2F-4 to etoposide inhibits gene transcrip-
tion mediated by the heterodimeric E2F-
4/DP complexes in the nucleus.  
Etoposide can affect transcription also 
through the bridging integrator-1 (BIN1) 
protein originally identified as a c-MYC-
interacting pro-apoptotic tumor suppressor. 
Several splice variants of BIN1 harbor a 
MYC-binding domain (MBD), thus retaining 
the ability to physically interact with and 
hence to inhibit the oncogenic functions of c-
MYC. Krainer group (Karni et al., 2007) 
showed that etoposide enhances the interac-
tion of E2F1 transcription factor with the 
BIN1 gene promoter. Notably, suppression 
of BIN1 expression using an antisense (AS) 
technique attenuated the cell death mediated 
by E2F1 and etoposide. 
Etoposide can also affect gene expression 
by modulating alternative splicing profiles. 
Alternative splicing is a co-transcriptional 
event that expands the coding capacity of the 
genome by affecting the vast majority (more 
than 90 %) of human genes (Pan et al., 
2008). A proteomic analysis to quantify 
DNA damage-regulated changes in phos-
phoproteome, acetylome, and proteome in 
human osteosarcoma cells treated with 
etoposide showed that a significant fraction 
of the hits corresponds to proteins involved 
in RNA metabolism such as THRAP3 (thy-
roid hormone receptor-associated protein 3), 
which is part of a multiprotein complex that 
controls Cyclin D1 mRNA stability, and the 
splicing-regulator phosphatase protein phos-
phatase Mg2+/Mn2+ dependent 1G (PPM1G), 
a nuclear member of the PP2C family of 
Ser/Thr phosphatases (Beli et al., 2012). In 
particular, the splicing-regulator phosphatase 
PPM1G is recruited to sites of DNA damage, 
while the splicing-associated protein 
THRAP3 is excluded from these regions. 
In line with the results of large-scale pro-
teomic analysis (Matsuoka et al., 2007; Beli 
et al., 2012) we have recently observed that 
the cell response to DNA damage affects the 
level and post-translational modifications of 
RNA binding proteins including splicing 
regulators belonging to the SR family and 
hnRNP proteins (Leva et al., 2012; Mon-
tecucco and Biamonti, 2013). Exposure of 
the cells to 100 µm etoposide for 3 h induces 
dephosphorylation of splicing factor SRSF1 
(previously known as SF2/ASF) that controls 
alternative splicing of several genes involved 
in the choice between pro- and anti-apoptotic 
pathways (Moore et al., 2010) including Ron 
oncogene (Biamonti et al., 2014; Ghigna et 
al., 2005) and tumor suppressor BIN1 (Karni 
et al., 2007). Changes in the phosphorylation 
status of SRSF1 in response to DNA damage 
results in modulation of the alternative splic-
ing profile of caspase 9 (Leva et al., 2012; 
Shultz et al., 2010) pointing to alternative 
splicing as a molecular mechanism actively 
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involved in the apoptotic effect of this drug. 
The list of genes whose alternative splicing 
is affected by genotoxic stress includes the 
CDC25 phosphatase that is essential for cell 
cycle control under normal conditions and in 
response to DNA damage. Notably, etopo-
side, doxorubicin, and the TopoI poison 
camptothecin alter the balance between 
CDC25 splice variants in human breast can-
cer cell lines both at the mRNA and protein 
levels (Albert et al., 2012).  
 
CELL DEATH 
Apoptosis 
Failure to properly repair DNA damages 
induces the activation of the process of pro-
grammed cell death or apoptosis that in-
volves a family of conserved cysteine-
dependent proteases called caspases (Riedl 
and Shi, 2004). 
It is known that high etoposide concen-
trations can trigger caspase-mediated apop-
tosis which mainly occurs through the cyto-
crome c/caspase 9 pathway (Wang et al., 
2006). After a genotoxic insult, in the early 
phases of apoptosis, cytocrome c is released 
from the mitochondria into the cytoplasm 
and binds to apoptotic protease activating 
factor 1 (apaf1) forming the apoptosome 
that, in turn, binds and cleaves procaspase 9 
leading to its activation. Caspase 9 is then 
able to activate other effector caspases such 
as caspase 7 and caspase 3 triggering further 
apoptotic processes (Figure 2).  
There are also evidences of the involve-
ment of a Fas ligand (FasL) pathway in 
etoposide-mediated apoptosis (Kaufmann 
and Earnshaw, 2000). Etoposide treatment 
triggers FasL binding to its receptor (FasR) 
on cell membrane. This results in trimeriza-
tion of the FasL-FasR complex and leads to 
the formation of the so-called death-inducing 
signalling complex (DISC). DISC-binding 
protein FADD is likely to bind procaspase 8 
and to promote its activation to capsase 8 
through self-cleavage. Caspase 8, in turn, 
interacts with some effector caspases such as 
caspase 3. 
 
Figure 2: Schematic representation of the apop-
totic pathway induced by genotoxic stress de-
scribed in the text 
 
 
As stated above etoposide treatment in-
duces the formation of DSBs also in non-
replicating cells thus perturbing gene tran-
scription. This has been proven in resting 
human T lymphocytes where etoposide 
treatment activates DDR and induces phos-
phorylation of ATM and of its substrates, 
H2AX and p53. The final effect is the activa-
tion of the pro-apoptotic PUMA (p53 upreg-
ulated modulator of apoptosis) protein and of 
caspases, leading to apoptotic cell death. In-
triguingly, in resting cells inhibition of ATM 
activity with Ku55933 blocks DDR and 
apoptosis by preventing PUMA expression 
and caspase activation, while the same pro-
tocol increases the cytotoxic effects of 
etoposide on proliferating tumor cells (Kor-
wek et al., 2012). This opens new avenue for 
antitumor strategies.  
The tumor suppressor p53 plays an im-
portant role in etoposide-induced apoptosis 
and is finely regulated by the drug (Dey et 
al., 2010). It has been recently shown that 
the Nemo-like serine/threonine kinase 
(NLK), a member of the mitogen activated 
kinase protein family, is required for p53 ac-
tivation after etoposide-induced DNA dam-
age (Zhang et al., 2014). The expression of 
the NLK gene is upregulated in response to 
DDR pathways, even if the mechanism in-
volved is still unclear. The interaction with 
NLK stabilizes p53 through the inhibition of 
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the MDM2-mediated degradation of the pro-
tein, mediated by the ubiquitin-proteasome 
system (Zhang et al., 2014; Kruse and Gu, 
2009). NLK may also increase the sensitivity 
to etoposide-induced apoptosis by suppress-
ing transcriptional factors such as NF-κB 
(Yasuda et al., 2004; Fan et al., 2008a).  
 
Autophagy 
Autophagy is a catabolic pathway that 
helps cells to degrade unnecessary or mis-
folded components and to recycle nutrients 
during metabolic stress. Although autophagy 
can be seen as a cellular pro-survival mecha-
nism, it can also promote non-apoptotic pro-
grammed cell death (reviewed by 
(Nagelkerke et al., 2014a, b). The autophagic 
pathways can be divided into macroautopha-
gy, microautophagy, and chaperone-
mediated autophagy (Figure 3).  
 
Figure 3: Schematic representation of the au-
tophagic pathways described in the text 
 
 
In macroautophagy, a membranous struc-
ture called autophagosome is formed through 
different steps: initiation, that requires the 
inhibition of mTOR pathway (Kamada et al., 
2000); nucleation, that is controlled by the 
activity of hVps34 kinase and its interacting 
proteins beclin-1 and p150/Vps35 to form 
the so called PI-3K (phosphatidylinositide 3-
kinase) complex on the membrane of the 
preautophagosome; enlongation, in which 
the preautophagosome membrane grows and 
fuses its extremities thanks to the action of 
the atg5-atg12-atg16 protein complex. Once 
the autophagosome is correctly assembled it 
maturates by fusing with a lysosome giving 
raise to an autophago-lysosome (Liang et al., 
2008). Macroautophagy can also be a selec-
tive pathway since the component of auto-
phagosome, LC3 protein, interacts with P62, 
leading polyubiquitinated proteins into the 
autophago-lysosome for degradation (Pankiv 
et al., 2007).  
Microautophagy is a process involved in 
the degradation of entire regions of cytosol 
directly performed by lysosomes through 
membrane invagination or evagination and 
without the formation of autophagolyso-
somes (Klionsky, 2005). Finally, chaperone-
mediated autophagy is a selective mecha-
nism by which hsc70 chaperone bound to 
KFERQ-motif-containing proteins, binds to 
the lysosomial membrane by interacting with 
LAMP2a receptor and internalizes the un-
folded target protein into the lysosome for 
degradation.  
Etoposide is a well-known trigger of 
apoptotic pathways but recent findings sug-
gest its involvement in autophagic pathways 
as well. It is still unclear, however, if the in-
duction of autophagic processes by etoposide 
causes cell death or plays a pro-survival 
function. In this regard it is worth noticing 
that Katayama and colleagues have shown 
that etoposide induces an autophagy-
dependent production of ATP in multiple 
glioma cells that actually protects cells and 
may contribute to drug resistance (Katayama 
et al., 2007). This increase in ATP levels can 
not be blocked by glucose starvation, but is 
prevented by preincubation with the auto-
phagy inhibitor 3-methyladenine (3-MA), or 
by siRNA–mediated down-regulation of be-
clin 1, or by the mitochondrial inhibitor oli-
gomycin. All these treatments, by inhibiting 
the production of autophagy-induced ATP, 
increase non-apoptotic cell death. These re-
sults have been confirmed by Bu Sham and 
colleagues in HepG2 cells (Xie et al., 2011). 
Collectively these analyses support the idea 
that DNA damaging agents such as etoposide 
may induce an autophagy-associated ATP 
surge that protects the cells and contributes 
to drug resistance (Katayama et al., 2007).  
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However, a study aimed at dissecting the 
mechanism by which etoposide induces cell 
death, showed that etoposide treatment of 
Hep3B hepatoma cells causes not only apop-
totic but also autophagic phenotypes. Au-
tophagy inhibition by 3-MA and caspase in-
hibition by zVAD-fmk effectively decreased 
autophagic and apoptotic phenotypes, re-
spectively. However, both drugs when used 
separately only partially prevented cell death 
indicating that etoposide concomitantly in-
duces autophagic cell death and apoptosis in 
Hep3B cells (Yoo et al., 2012).  
 
Acknowledgements 
We apologize to colleagues whose work 
could only be cited indirectly. This work has 
been supported by grants from the Associa-
zione Italiana per la Ricerca sul Cancro 
AIRC, the PNR-CNR Aging Program 2012–
2014 CNR-MIUR, the Flagship project 
Epigen CNR-MIUR, the MbMM project 
2014-2015 Accordo Quadro Regione Lom-
bardia–CNR to GB. FZ is a student of the 
PhD program in Genetics, Molecular and 
Cellular Biology of the University of Pavia 
and is supported by a fellowship of the 
MbMM project. 
 
REFERENCES 
Adachi N, Suzuki H, Liizumi S, Koyama H. Hyper-
sensitivity of nonhomologous DNA end-joining mu-
tants to VP-16 and ICRF-193: implications for the 
repair of topoisomerase II-mediated DNA damage. J 
Biol Chem. 2003;278:35897–902. 
Albert H, Battaglia E, Monteiro C, Bagrel D. Geno-
toxic stress modulates CDC25C phosphatase alterna-
tive splicing in human breast cancer cell lines. Mol 
Oncol. 2012;6:542–52. 
Azarova AM, Lyu YL, Lin C-P, Tsai, Y-C, Lau JY-N, 
Wang JC, et al. Roles of DNA topoisomerase II iso-
zymes in chemotherapy and secondary malignancies. 
Proc Natl Acad of Sci USA. 2007;104:11014–9. 
Bartek J, Lukas J. DNA damage checkpoints: from 
initiation to recovery or adaptation. Curr Opin Cell 
Biol. 2007;19:238–45. 
Beli P, Lukashchuk N, Wagner SA, Weinert BT, Ol-
sen JV, Baskomb L, et al. Proteomic investigations 
reveal a role for RNA processing factor THRAP3 in 
the DNA damage response. Mol Cell. 2012;46:212–
25. 
Biamonti G, Catillo M, Pignataro D, Montecucco A, 
Ghigna C. The alternative splicing side of cancer. 
Semin Cell Dev Biol. 2014;32:30–6. 
Boisvert FM, Lam YW, Lamont D, Lamond A. A 
quantitative proteomics analysis of subcellular prote-
ome localization and changes induced by DNA dam-
age. Mol Cell Proteomics. 2010;9:457–70. 
Caporossi D, Porfirio B, Nicoletti B, Palitti F, De Sal-
via R, et al. Hypersensitivity of lymphoblastoid lines 
derived from ataxia telangiectasia patients to the in-
duction of chromosomal aberrations by etoposide 
(VP-16). Mutat Res. 1993;290:265–72. 
Chamani E, Rabbani-Chadegani A, Zahraei Z. Spec-
troscopic detection of etoposide binding to chromatin 
components: The role of histone proteins. Spectro-
chim Acta A Mol Biomol Spectrosc. 2014;133:292–9. 
Chen C-S, Wang, Y-C, Yang H-C, Huang P-H, Kulp 
SK, Yang C-C, et al. Histone deacetylase inhibitors 
sensitize prostate cancer cells to agents that produce 
DNA double-strand breaks by targeting Ku70 acetyla-
tion. Cancer Res. 2007;67:5318–27. 
Chen SH, Chan N-L, Hsieh T-S. New mechanistic 
and functional insights into DNA topoisomerases. 
Annu Rev Biochem. 2013;82:139–70. 
Cortes Ledesma F, El Khamisy SF, Zuma MC, Os-
born K, Caldecott KW. A human 5'-tyrosyl DNA 
phosphodiesterase that repairs topoisomerase-
mediated DNA damage. Nature. 2009;461:674–8. 
Cowell IG, Papageorgiou N, Padget K, Watters GP, 
Austin CA. Histone deacetylase inhibition redistrib-
utes topoisomerase IIβ from heterochromatin to eu-
chromatin. Nucleus. 2011;2:61–71. 
Dellaire G, Kepkay R, Bazett-Jones DP. High resolu-
tion imaging of changes in the structure and spatial 
organization of chromatin, gamma-H2A.X and the 
MRN complex within etoposide-induced DNA repair 
foci. Cell Cycle. 2009;8:3750–69. 
Dey A, Lane DP, Verma CS. Modulating the p53 
pathway. Semin Cancer Biol. 2010;20:3–9. 
Fan Y, Dutta J, Gupta N, Fan G, Gelinas C. Regula-
tion of programmed cell death by NF-kappaB and its 
role in tumorigenesis and therapy. Adv Exp Med Biol. 
2008a;615:223–50. 
EXCLI Journal 2015;14:95-108 – ISSN 1611-2156 
Received: August 29, 2014, accepted:October 24, 2014, published: January 19, 2015 
 
 
105 
Fan JR, Peng A-L, Chen H-C, Lo S-C Huang T-H, Li 
T-K. Cellular processing pathways contribute to the 
activation of etoposide-induced DNA damage re-
sponses. DNA Repair (Amst). 2008b;7:452–63. 
Gao R, Shellenberg MJ, Huang S-HN, Abdelmalak 
M, Marchand C, Nitiss, KC, et al. Proteolytic degra-
dation of topoisomerase II (Top2) enables the pro-
cessing of Top2·DNA and Top2·RNA covalent com-
plexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2). 
J Biol Chem. 2014;289:17960–9. 
Ghigna C, Giordano S, Shen H, Benvenuto F, 
Castiglioni F, Comoglio PM. Cell motility is con-
trolled by SF2/ASF through alternative splicing of the 
Ron protooncogene. Mol Cell. 2005;20:881–90. 
Giglia-Mari G, Zotter A, Vermeulen W. DNA dam-
age response. Cold Spring Harb Perspect Biol. 
2011;3:a000745. 
Glozak MA, Sengupta N, Zhang X, Seto E. Acetyla-
tion and deacetylation of non-histone proteins. Gene. 
2005;363:15–23. 
Hajji N, Wallenborg K, Vlachos P, Nyman U, Her-
manson O, Joseph B. Combinatorial action of the 
HDAC inhibitor trichostatin A and etoposide induces 
caspase-mediated AIF-dependent apoptotic cell death 
in non-small cell lung carcinoma cells. Oncogene. 
2008;27:3134–44. 
Hajji N, Wallenborg K, Vlachos P, Fullgrabe J, Her-
manson O, Joseph B. Opposing effects of hMOF and 
SIRT1 on H4K16 acetylation and the sensitivity to the 
topoisomerase II inhibitor etoposide. Oncogene. 
2010;29:2192–204. 
Hamilton NK, Maizels N. MRE11 function in re-
sponse to topoisomerase poisons is independent of its 
function in double-strand break repair in Saccharo-
myces cerevisiae. PLoS ONE. 2010;5:15387. 
Hande KR. Etoposide: four decades of development 
of a topoisomerase II inhibitor. Eur J Cancer. 1998; 
34:1514–21. 
Hansen LT, Lundin C, Helleday T, Poulsen HS, 
Sorensen CS, Petersen LN, et al. DNA repair rate and 
etoposide (VP16) resistance of tumor cell subpopula-
tions derived from a single human small cell lung 
cancer. Lung Cancer. 2003;40:157–64. 
Hartsuiker E, Neale MJ, Carr AM. Distinct require-
ments for the Rad32(Mre11) nuclease and Ctp1(CtIP) 
in the removal of covalently bound topoisomerase I 
and II from DNA. Mol Cell. 2009;33:117–23. 
Hermanson O, Glass CK, Rosenfeld MG. Nuclear 
receptor coregulators: multiple modes of modifica-
tion. Trends Endocrinol Metab. 2002;13:55–60. 
Huang H-S, Allen JA, Mabb AM, King IF, Miriyala J, 
Taylor-Blake B. Topoisomerase inhibitors unsilence 
the dormant allele of Ube3a in neurons. Nature. 
2012;481:185–9. 
Kakarougkas A, Jeggo PA. DNA DSB repair pathway 
choice: an orchestrated handover mechanism. Br J 
Radiol. 2014;87:20130685. 
Kamada Y, Funakoshi T, Shintani T, Nagano K, 
Ohsumi M, Ohsumi Y. Tor-mediated induction of 
autophagy via an Apg1 protein kinase complex. J Cell 
Biol. 2000;150:1507–13. 
Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, 
Krainer AR. The gene encoding the splicing factor 
SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 
2007;14:185–93. 
Katayama M, Kawaguchi T, Berger MS, Pieper OR. 
DNA damaging agent-induced autophagy produces a 
cytoprotective adenosine triphosphate surge in malig-
nant glioma cells. Cell Death Differ. 2007;14:548–58. 
Kaufmann SH, Earnshaw WC. Induction of apoptosis 
by cancer chemotherapy. Exp Cell Res. 2000;256:42–
9. 
Klionsky DJ. Autophagy. Curr Biol. 2005;15:R282–3. 
Korwek Z, Sewastianik T, Bielak-Zmijewska A, 
Mosieniak G, Alster O, Moreno-Villaneuva M, et al. 
Inhibition of ATM blocks the etoposide-induced 
DNA damage response and apoptosis of resting hu-
man T cells. DNA Repair (Amst). 2012;11:864–73. 
Kruse J-P, Gu W. Modes of p53 regulation. Cell. 
2009;137:609–22. 
Leva V, Giulano S, Bardoni A, Camerini S, Crescenzi 
M, Lisa A, et al. Phosphorylation of SRSF1 is modu-
lated by replicational stress. Nucleic Acids Res. 2012; 
40:1106–17. 
Liang C, Sir D, Lee S, Ou J-HJ, Jung JU. Beyond 
autophagy: the role of UVRAG in membrane traffick-
ing. Autophagy. 2008;4:817–20. 
Liu H, Hu Q, D'ercole AJ, Ye P. Histone deacetylase 
11 regulates oligodendrocyte-specific gene expression 
and cell development in OL-1 oligodendroglia cells. 
Glia. 2009;57:1–12. 
Lovett BD, Lo Nigro L, Rappaport EF, Blair A, 
Osheroff N, Zheng N, et al. Near-precise interchro-
mosomal recombination and functional DNA topoi-
somerase II cleavage sites at MLL and AF-4 genomic 
breakpoints in treatment-related acute lymphoblastic 
leukemia with t(4;11) translocation. Proc Natl Acad 
Sci USA. 2001a;98:9802–7. 
EXCLI Journal 2015;14:95-108 – ISSN 1611-2156 
Received: August 29, 2014, accepted:October 24, 2014, published: January 19, 2015 
 
 
106 
Lovett BD, Strumberg D, Blair A, Pang S, Burden 
DA, Magonigal MD, et al. Etoposide metabolites en-
hance DNA topoisomerase II cleavage near leukemia-
associated MLL translocation breakpoints. Biochem-
istry. 2001b;40:1159–70. 
Lyu YL, Lin YL, Azarova AM, Cai L, Wang JC, Liu 
LF. Role of topoisomerase IIbeta in the expression of 
developmentally regulated genes. Mol Cell Biol. 
2006;26:7929–41. 
Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL. 
Roles of nonhomologous end-joining pathways in 
surviving topoisomerase II-mediated DNA damage. 
Mol Cancer Ther. 2006;5:1405–14. 
Maréchal A, Zou L. DNA damage sensing by the 
ATM and ATR kinases. Cold Spring Harb Perspect 
Biol. 2013;5(9); epub ahead of print. 
Maser RS, Monsen RS, Nelms BE, Petrini JH. 
hMre11 and hRad50 nuclear foci are induced during 
the normal cellular response to DNA double-strand 
breaks. Mol Cell Biol. 1997;17:6087–96. 
Matsuoka S, Ballif BA, Smogorzewska A, McDonald 
ER, Hurov KEH. ATM and ATR substrate analysis 
reveals extensive protein networks responsive to 
DNA damage. Science. 2007;316:1160–6. 
Monte M, Simonatto M, Peche LY, Bublik DR, Go-
bessi S, Pierotti MA, et al. MAGE-A tumor antigens 
target p53 transactivation function through histone 
deacetylase recruitment and confer resistance to 
chemotherapeutic agents. Proc Natl Acad Sci USA. 
2006;103:11160–5. 
Montecucco A, Biamonti G. Pre-mRNA processing 
factors meet the DNA damage response. Front Genet. 
2013;4:102. 
Montecucco A, Rossi R, Ferrari G, Scovassi AI, 
Prosperi E, Biamonti G. Etoposide induces the disper-
sal of DNA ligase I from replication factories. Mol 
Biol Cell. 2001;12:2109–18. 
Moore MJ, Wang Q, Kennedy CL, Silver PA. An 
alternative splicing network links cell-cycle control to 
apoptosis. Cell. 2010;142:625–36. 
Nagelkerke A, Sweep FCGJ, Geurts-Moespot A, Bus-
sink J, Span PN. Therapeutic targeting of autophagy 
in cancer. Part I: Molecular pathways controlling au-
tophagy. Semin Cancer Biol. 2014a; 
doi:10.1016/j.semcancer.2014.05.004. epub ahead of 
print. 
Nagelkerke A, Bussink J, Geurts-Moespot A, Sweep 
FCGJ, Span PN. Therapeutic targeting of autophagy 
in cancer. Part II: Pharmacological modulation of 
treatment-induced autophagy. Semin Cancer Biol. 
2014b; doi:10.1016/j.semcancer.2014.06.001. epub 
ahead of print. 
Nakada S, Katsuki Y, Imoto I, Yokoyama T, Naga-
sawa M, Inazawa J, et al. Early G2/M checkpoint 
failure as a molecular mechanism underlying etopo-
side-induced chromosomal aberrations. J Clin Invest. 
2006;116:80–9. 
Nayak MS, Yang J-M, Hait WN. Effect of a single 
nucleotide polymorphism in the murine double mi-
nute 2 promoter (SNP309) on the sensitivity to topoi-
somerase II-targeting drugs. Cancer Res. 2007;67: 
5831–9. 
Nitiss JL. DNA topoisomerase II and its growing rep-
ertoire of biological functions. Nat Rev Cancer. 2009; 
9:327–37. 
Nitiss KC, Malik M, He X, White SW, Nitiss JL. Ty-
rosyl-DNA phosphodiesterase (Tdp1) participates in 
the repair of Top2-mediated DNA damage. Proc Natl 
Acad Sci USA. 2006;103:8953–8. 
Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep 
surveying of alternative splicing complexity in the 
human transcriptome by high-throughput sequencing. 
Nat Genet. 2008;40:1413–5. 
Pankiv S, Clausen TH, Lamark T, Brech A, Bruun J-
A, Outzen H, et al. p62/SQSTM1 binds directly to 
Atg8/LC3 to facilitate degradation of ubiquitinated 
protein aggregates by autophagy. J Biol Chem. 2007; 
282:24131–45. 
Pedersen-Bjergaard J, Andersen MK, Christiansen 
DH. Nerlov C. Genetic pathways in therapy-related 
myelodysplasia and acute myeloid leukemia. Blood. 
2002a;99:1909–12. 
Pedersen-Bjergaard J, Christiansen DH, Andersen 
MK, Skovby F. Causality of myelodysplasia and 
acute myeloid leukemia and their genetic abnormali-
ties. Leukemia. 2002b;16:2177–84. 
Polo SE, Jackson SP. Dynamics of DNA damage re-
sponse proteins at DNA breaks: a focus on protein 
modifications. Genes Dev. 2011;25:409–33. 
Riedl SJ, Shi Y. Molecular mechanisms of caspase 
regulation during apoptosis. Nat Rev Mol Cell Biol. 
2004;5:897–907. 
Rossi R, Montecucco A, Donzelli M, Denegri M, Bi-
amonti G, Scovassi A. DNA ligase I is dephosphory-
lated during the execution step of etoposide-induced 
apoptosis. Cell Death Differ. 2002;9:89–90. 
EXCLI Journal 2015;14:95-108 – ISSN 1611-2156 
Received: August 29, 2014, accepted:October 24, 2014, published: January 19, 2015 
 
 
107 
Rossi R, Lidonnici MR, Spza S, Biamonti G, Mon-
tecucco A. The dispersal of replication proteins after 
Etoposide treatment requires the cooperation of Nbs1 
with the ataxia telangiectasia Rad3-related/Chk1 
pathway. Cancer Res. 2006;66:1675–83. 
Rubtsov MA, Terekhov SM, Razin SV, Iarovaia OV. 
Repositioning of ETO gene in cells treated with VP-
16, an inhibitor of DNA-topoisomerase II. J Cell Bio-
chem. 2008;104:692–9. 
Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bar-
tek J, et al. Human CtIP promotes DNA end resection. 
Nature. 2007;450:509–14. 
Schneider R, Grosschedl R. Dynamics and interplay 
of nuclear architecture, genome organization, and 
gene expression. Genes Dev. 2007;21:3027–43. 
Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, 
Hawkins AJ, Shay JW, et al. Alternative splicing of 
caspase 9 is modulated by the phosphoinositide 3-
kinase/Akt pathway via phosphorylation of SRp30a. 
Cancer Res. 2010;70:9185–96. 
Takami M, Takakusagi Y, Kuramochi K, Tsukuda S, 
Aoki S, Morohashi K, et al. A screening of a library 
of T7 phage-displayed peptide identifies E2F-4 as an 
etoposide-binding protein. Molecules. 2011;16:4278–
94. 
Taniura H, Matsumoto K, Yoshikawa K. Physical and 
functional interactions of neuronal growth suppressor 
necdin with p53. J Biol Chem. 1999;274:16242–8. 
Tiwari VK, Burger L, Nikoletopoulou V, Deogracias 
R, Thakurela S, Wirbelauer C, et al. Target genes of 
Topoisomerase IIβ regulate neuronal survival and are 
defined by their chromatin state. Proc Natl Acad Sci 
USA. 2012;109:E934–43. 
Tong JK, Hassig CA, Schnitzler GR, Kingston RE, 
Schreiber SL. Chromatin deacetylation by an ATP-
dependent nucleosome remodelling complex. Nature 
1998;395:917–21. 
Tsai AP, Guo JQ, Abe E, Takakura H, Sato TJ. A 
stable binary quasicrystal. Nature. 2000;408:537–8. 
van der Bruggen P, Traversari C, Chomez P, Lurquin 
C, De Plaen E, Van den Eynde B, et al. A gene encod-
ing an antigen recognized by cytolytic T lymphocytes 
on a human melanoma. Science. 1991;254:1643–7. 
Wang P, Song JH, Song DK, Zhang J, Hao C. Role of 
death receptor and mitochondrial pathways in conven-
tional chemotherapy drug induction of apoptosis. Cell 
Signal. 2006;18:1528–35. 
Wen C-J, Xue B, Qin W-X, Yu M, Zhang M-Y, Zhao 
D-H, et al. hNRAGE, a human neurotrophin receptor 
interacting MAGE homologue, regulates p53 tran-
scriptional activity and inhibits cell proliferation. 
FEBS Lett. 2004;564:171–6. 
Wilstermann AM, Bender RP, Godfrey M, Choi S, 
Anklin C, Berkowitz DB, et al. Topoisomerase II - 
drug interaction domains: identification of substitu-
ents on etoposide that interact with the enzyme. Bio-
chemistry. 2007;46:8217–25. 
Wong AK, OrmondePA, Pero R, Chen Y, Lian L, 
Salada G, et al. Characterization of a carboxy-
terminal BRCA1 interacting protein. Oncogene. 1998; 
17:2279–85. 
Wu C-C, Li T-C, Farh L, Lin L-Y, Lin T-S, Yu Y-J, 
et al. Structural basis of type II topoisomerase inhibi-
tion by the anticancer drug etoposide. Science. 
2011;333:459–62. 
Xie B-S, Zhao H-C, Yao S-K, Zhuo D-X, Jin B, Lv 
D-C, et al. Autophagy inhibition enhances etoposide-
induced cell death in human hepatoma G2 cells. Int J 
Mol Med. 2011;27:599–606. 
Yang X, Li W, Prescott ED, Burdern SJ, Wang JC. 
DNA topoisomerase IIbeta and neural development. 
Science. 2000;287:131–4. 
Yasuda J, Yokoo H, Yamada T, Kitabayashi I, Sekiya 
T, Ichikawa H. Nemo-like kinase suppresses a wide 
range of transcription factors, including nuclear fac-
tor-kappaB. Cancer Sci. 2004;95:52–7. 
Yoo SH, Yoon YG, Lee JS, Song YS, Oh JS, Park 
BS, et al. Etoposide induces a mixed type of pro-
grammed cell death and overcomes the resistance 
conferred by Bcl-2 in Hep3B hepatoma cells. Int J 
Oncol. 2012;41:1443–54. 
Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R. 
The C-terminal (BRCT) domains of BRCA1 interact 
in vivo with CtIP, a protein implicated in the CtBP 
pathway of transcriptional repression. J Biol Chem. 
1998;273:25388–92. 
Zeng Z, Cortes Ledesma F, El Khamisy SF, Cak-
decott KW. TDP2/TTRAP is the major 5'-tyrosyl 
DNA phosphodiesterase activity in vertebrate cells 
and is critical for cellular resistance to topoisomerase 
II-induced DNA damage. J Biol Chem. 2011;286: 
403–9. 
Zhang A, Lyu YL, Lin C-P, Zhou N, Azarova A, 
Wood LM, et al. A protease pathway for the repair of 
topoisomerase II-DNA covalent complexes. J Biol 
Chem. 2006;281:35997–6003. 
EXCLI Journal 2015;14:95-108 – ISSN 1611-2156 
Received: August 29, 2014, accepted:October 24, 2014, published: January 19, 2015 
 
 
108 
Zhang H-H, Li S-Z, Zhang Z-Y, Hu X-M, Hou P-N, 
Gao L, et al. Nemo-like kinase is critical for p53 sta-
bilization and function in response to DNA damage. 
Cell Death Differ. 2014;21:1656-63. 
Zhang Y, Strissel P, Strick R, Chen J, Nucifora G, Le 
Beau MM, et al. Genomic DNA breakpoints in 
AML1/RUNX1 and ETO cluster with topoisomerase 
II DNA cleavage and DNase I hypersensitive sites in 
t(8;21) leukemia. Proc Natl Acad Sci USA. 2002;99: 
3070–5. 
